<p><img src="https://imageproxy.pbkrs.com/https://www.drugdiscoverytrends.com/wp-content/uploads/2023/04/AdobeStock_577842756-300x195.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.drugdiscoverytrends.com/wp-content/uploads/2023/04/AdobeStock_577842756-300x195.jpg"/></p>
<p>[sizsus/Adobe Stock]</p>
<p>製藥行業的傳統層級正面臨多年來最強烈的挑戰，預計 2024 年的收入顯示出領導者之間的動態變化。雖然默克（$63.9B）和輝瑞（$62.5B）佔據了前兩位，但阿斯利康（+17.9%）、禮來（+33.9%）和諾和諾德（+26.1%）的兩位數增長則預示着該行業競爭格局的加速轉變。</p>
<p>GLP-1 市場的持續強勁仍然是市場的顛覆者，但這些藥物在可及性、成本和市場滲透方面也面臨複雜的挑戰。</p>
<p>阿斯利康在 GLP-1 療法佔據主導地位的市場中成為了一個意外的成功故事。其強大的產品組合和在關鍵治療領域的表現幫助推動了前九個月總收入增長 19%，達到 391.82 億美元。腫瘤學、心血管、腎臟與代謝（CVRM）以及呼吸與免疫學（R&amp;I）的增長率分別為 22%、21% 和 24%，稀有疾病的增長率也達到了 14%。像 Farxiga 和 Enhertu 這樣的關鍵產品在第三季度分別貢獻了 34% 和 60% 的增長。阿斯利康還宣佈在美國進行 20 億美元的研發和製造投資，並應對了中國的監管挑戰。因此，阿斯利康上調了 2024 年的全年指導，預計總收入和核心每股收益將實現高個位數的百分比增長。</p>
<p>在整體收入方面，默克公司在 2024 年繼續保持穩定的軌跡，預計全球銷售額在 636 億美元到 641 億美元之間，年增長約為 5.8% 到 6.6%。然而，該公司的季度增長已放緩，從第一季度的 12%（不包括外匯影響）降至第三季度的 7%，這表明即使 Keytruda 的銷售依然強勁，仍可能面臨挑戰。輝瑞也在後疫情的複雜過渡中繼續前行，但儘管預計由於 COVID-19 產品銷售下降，年銷售額將下降約 36% 到 39%，該公司在第三季度表現突出。</p>
<p>以下是完整的預測。</p>
<table>
<thead>
<tr>
<th><strong>排名</strong></th>
<th><strong>公司</strong></th>
<th><strong>2023 年收入</strong></th>
<th><strong>2024 年預測</strong></th>
<th><strong>預計增長</strong></th>
<th><strong>關鍵財務亮點</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>默克</td>
<td>$60.12B</td>
<td>$63.85B</td>
<td>+6.2%</td>
<td>Q1-Q3: 9%, 7%, 4% 增長軌跡；剔除外匯影響的強勁勢頭（Q1: 12%, Q3: 7%）；指導：$63.6B-$64.1B</td>
</tr>
<tr>
<td>2</td>
<td>輝瑞</td>
<td>$58.50B</td>
<td>$62.50B</td>
<td>+6.8%</td>
<td>Q3 顯示恢復：31% 增長；COVID 影響已納入指導；最近的指導上調：$61.0B-$64.0B</td>
</tr>
<tr>
<td>3</td>
<td>阿斯利康</td>
<td>$45.81B</td>
<td>$54.00B</td>
<td>+17.9%</td>
<td>一致的高個位數增長（Q1-Q3: 19%, 17%, 21%）；年初至今：$39.18B (+19%); 各季度強勁勢頭。指導在 “高個位數” 範圍內。</td>
</tr>
<tr>
<td>4</td>
<td>羅氏</td>
<td>$51.45B</td>
<td>$53.50B</td>
<td>+4.0%</td>
<td>Q1-Q3: 加速增長（2%, 5%, 9%）；年初至今：6% CER 增長；中個位數指導</td>
</tr>
<tr>
<td>5</td>
<td>強生</td>
<td>$50.93B</td>
<td>$53.48B</td>
<td>+5.0%</td>
<td>製藥部門穩定在 5.5% 增長</td>
</tr>
<tr>
<td>6</td>
<td>賽諾菲</td>
<td>$46.59B</td>
<td>$52.97B</td>
<td>+13.7%</td>
<td>加速增長（5.7%, 10.2%, 15.7%）；強勁的 Q3：€13.44B；上調每股收益指導</td>
</tr>
<tr>
<td>7</td>
<td>諾華</td>
<td>$45.44B</td>
<td>$49.94B</td>
<td>+9.9%</td>
<td>穩定增長（7%, 9%, 10%）；低雙位數指導；強勁的營業收入</td>
</tr>
<tr>
<td>8</td>
<td>百時美施貴寶</td>
<td>$45.01B</td>
<td>$47.44B</td>
<td>+5.4%</td>
<td>一致增長（5%, 9%, 8%）；~5% 收入增長指導；Q2 表現穩健，增長 9%</td>
</tr>
<tr>
<td>9</td>
<td>禮來</td>
<td>$34.12B</td>
<td>$45.70B</td>
<td>+33.9%</td>
<td>市場領先的 Q2/Q3（36%, 20%）；明確的指導：$45.4B-$46.0B；關鍵產品強勁勢頭</td>
</tr>
<tr>
<td>10</td>
<td>諾和諾德</td>
<td>$33.71B</td>
<td>$42.50B</td>
<td>+26.1%</td>
<td>Q3: 21% 增長；Wegovy 銷售增長 84%；Ozempic 銷售增長 28%；指導：23-27% 增長</td>
</tr>
<tr>
<td>11</td>
<td>GSK</td>
<td>$37.73B</td>
<td>$40.23B</td>
<td>+6.6%</td>
<td>強勁的上半年（10%, 13%）；Q3 放緩至 2%；指導：7-9% 營業額增長</td>
</tr>
<tr>
<td>12</td>
<td>安進</td>
<td>$28.19B</td>
<td>$33.30B</td>
<td>+18.1%</td>
<td>一致的 20%+ 增長；Q1-Q3: 22%, 20%, 23%；指導：$32.8B-$33.8B</td>
</tr>
<tr>
<td>13</td>
<td>武田</td>
<td>$30.34B</td>
<td>$30.52B</td>
<td>+0.6%</td>
<td>強勁的上半年：14.1%, 13.4% 增長；上調預測至¥4,480B；優於最初的平穩指導</td>
</tr>
<tr>
<td>14</td>
<td>吉利德</td>
<td>$27.12B</td>
<td>$27.95B</td>
<td>+3.1%</td>
<td>Q3: 7% 增長；關鍵產品增長（Biktarvy +13%）；指導：$27.8B-$28.1B</td>
</tr>
<tr>
<td>15</td>
<td>拜耳</td>
<td>$17.78B</td>
<td>$17.23B</td>
<td>-3.0%</td>
<td>Q3 挑戰：3.6% 收入下降；EBITDA 下降 25.8%；謹慎的 2025 年展望</td>
</tr>
<tr>
<td>16</td>
<td>Teva</td>
<td>$15.85B</td>
<td>$16.30B</td>
<td>+2.8%</td>
<td>Q3: 13% 美元增長；強勁的產品表現；指導：$16.1B-$16.5B</td>
</tr>
<tr>
<td>17</td>
<td>大冢</td>
<td>$14.32B</td>
<td>$15.25B</td>
<td>+6.5%</td>
<td>Q3: 同比增長 17%；¥1,730.1B 預測；積極的利潤展望</td>
</tr>
<tr>
<td>18</td>
<td>Viatris</td>
<td>$15.43B</td>
<td>$15.05B</td>
<td>-2.5%</td>
<td>Q3: 3% 增長（剔除剝離影響）；指導：$14.6B-$15.1B；EBITDA：$5.0B-$5.3B 目標</td>
</tr>
<tr>
<td>19</td>
<td>CSL</td>
<td>$13.31B</td>
<td>$14.80B</td>
<td>+11.2%</td>
<td>CSL Behring: 14% 增長；Seqirus: 4% 增長；強勁的 NPATA 增長</td>
</tr>
<tr>
<td>20</td>
<td>Regeneron</td>
<td>$13.12B</td>
<td>$13.85B</td>
<td>+5.6%</td>
<td>Q3: 11% 增長；Dupixent 銷售增長 23%；產品銷售指導：$27.8B-$28.1B</td>
</tr>
</tbody>
</table>
<h3>方法論</h3>
<p>2024 年的收入預測最初基於過去四個季度報告的財務數據和公司的指導。數據來自公司報告和 finbox.com。對於提供直接指導的公司，預測與指導範圍的中點對齊。對於提供增長率指導而非具體收入目標的公司，預測是根據隱含的增長範圍計算的。</p>
<p>多元化公司需要針對特定細分市場進行調整，以準確估計製藥收入。這些調整包括強生 63.67%、羅氏 71.6%、拜耳 33.8%、默克 KGaA37.6% 和雅培 13.0% 的細分貢獻。</p>
<hr/>
<hr/>

輝瑞

禮來

諾和諾德公司

默克

<p>製藥行業正在經歷顯著的層級變化，默克和輝瑞在 2024 財年的預計收入中處於領先地位。阿斯利康、禮來和諾和諾德公司顯示出顯著的增長率，表明競爭格局正在發生轉變。阿斯利康在前九個月的收入增長了 19%，促使其上調了增長指引。儘管在後疫情環境中面臨挑戰，默克和輝瑞也保持了穩定的增長。報告概述了前 20 大製藥公司的收入預測，突出了關鍵財務指標和增長預期</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.drugdiscoverytrends.com/wp-content/uploads/2023/04/AdobeStock_577842756-300x195.jpg" alt="" original-src="https://www.drugdiscoverytrends.com/wp-content/uploads/2023/04/AdobeStock_577842756-300x195.jpg"/></p>
<p>[sizsus/Adobe Stock]</p>
<div class="lb-trans"><p>[sizsus/Adobe Stock]</p>
</div><p>The pharmaceutical industry’s traditional hierarchy is facing its strongest challenge in years, with projected 2024 revenues showing dynamic shifts among the leaders. While Merck ($63.9B) and Pfizer ($62.5B) hold the top spots, double-digit growth from AstraZeneca (+17.9%), Eli Lilly (+33.9%), and Novo Nordisk (+26.1%) signals an accelerating transformation in the sector’s competitive landscape.</p>
<div class="lb-trans"><p>製藥行業的傳統層級正面臨多年來最強烈的挑戰，預計 2024 年的收入顯示出領導者之間的動態變化。雖然默克（$63.9B）和輝瑞（$62.5B）佔據了前兩位，但阿斯利康（+17.9%）、禮來（+33.9%）和諾和諾德（+26.1%）的兩位數增長則預示着該行業競爭格局的加速轉變。</p>
</div><p>The continued strength of the GLP-1 market continues to be a market disruptor, but the medications also face complex challenges in terms of accessibility, cost, and market penetration.</p>
<div class="lb-trans"><p>GLP-1 市場的持續強勁仍然是市場的顛覆者，但這些藥物在可及性、成本和市場滲透方面也面臨複雜的挑戰。</p>
</div><p>AstraZeneca was something of a surprise success story in a landscape where GLP-1 therapies loom large. Its strong product portfolio and performance across key therapeutic areas helped propel total revenue 19% to $39,182 million in the first nine months of the year. Oncology, Cardiovascular, Renal and Metabolism (CVRM), and Respiratory and Immunology (R&amp;I) saw growth rates of 22%, 21%, and 24% respectively, complemented by 14% growth in rare disease. Key products like Farxiga and Enhertu contributed significantly, with growth rates of 34% and 60% respectively in Q3. AstraZeneca also announced a $2 billion investment in U.S. R&amp;D and manufacturing, and navigated regulatory challenges in China. As a result, AstraZeneca upgraded its full-year 2024 guidance, projecting high teens percentage growth for both Total Revenue and Core EPS.</p>
<div class="lb-trans"><p>阿斯利康在 GLP-1 療法佔據主導地位的市場中成為了一個意外的成功故事。其強大的產品組合和在關鍵治療領域的表現幫助推動了前九個月總收入增長 19%，達到 391.82 億美元。腫瘤學、心血管、腎臟與代謝（CVRM）以及呼吸與免疫學（R&amp;I）的增長率分別為 22%、21% 和 24%，稀有疾病的增長率也達到了 14%。像 Farxiga 和 Enhertu 這樣的關鍵產品在第三季度分別貢獻了 34% 和 60% 的增長。阿斯利康還宣佈在美國進行 20 億美元的研發和製造投資，並應對了中國的監管挑戰。因此，阿斯利康上調了 2024 年的全年指導，預計總收入和核心每股收益將實現高個位數的百分比增長。</p>
</div><p>Leading 2024 in terms of overall revenue areMerck &amp; Co., which continued to maintain a steady trajectory with projected worldwide sales between $63.6 billion and $64.1 billion, demonstrating approximately 5.8% to 6.6% annual growth. The company’s quarterly growth, however, has slowed, from 12% excluding foreign exchange in Q1 to 7% in Q3, indicating potential challenges even as Keytruda sales remain strong. Pfizer also continues to navigate a complex transition in a post-COVID landscape but the company had a standout third quarter despite anticipating an approximately 36% to 39% annual dip owing to decreased COVID-19 product sales.</p>
<div class="lb-trans"><p>在整體收入方面，默克公司在 2024 年繼續保持穩定的軌跡，預計全球銷售額在 636 億美元到 641 億美元之間，年增長約為 5.8% 到 6.6%。然而，該公司的季度增長已放緩，從第一季度的 12%（不包括外匯影響）降至第三季度的 7%，這表明即使 Keytruda 的銷售依然強勁，仍可能面臨挑戰。輝瑞也在後疫情的複雜過渡中繼續前行，但儘管預計由於 COVID-19 產品銷售下降，年銷售額將下降約 36% 到 39%，該公司在第三季度表現突出。</p>
</div><p>Here are the full projections.</p>
<div class="lb-trans"><p>以下是完整的預測。</p>
</div><table>
<thead>
<tr>
<th><strong>Rank</strong></th>
<th><strong>Company</strong></th>
<th><strong>2023 Revenue</strong></th>
<th><strong>2024 Projection</strong></th>
<th><strong>Projected Growth</strong></th>
<th><strong>Key Financial Highlights</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Merck</td>
<td>$60.12B</td>
<td>$63.85B</td>
<td>+6.2%</td>
<td>Q1-Q3: 9%, 7%, 4% growth trajectory; Strong momentum ex-FX (Q1: 12%, Q3: 7%); Guidance: $63.6B-$64.1B</td>
</tr>
<tr>
<td>2</td>
<td>Pfizer</td>
<td>$58.50B</td>
<td>$62.50B</td>
<td>+6.8%</td>
<td>Q3 showing recovery: 31% growth; COVID impact factored into guidance; Recent guidance raise: $61.0B-$64.0B</td>
</tr>
<tr>
<td>3</td>
<td>AstraZeneca</td>
<td>$45.81B</td>
<td>$54.00B</td>
<td>+17.9%</td>
<td>Consistent high-teens growth (Q1-Q3: 19%, 17%, 21%); YTD: $39.18B (+19%); Strong momentum across quarters. Guidance in the ‘high teens.’</td>
</tr>
<tr>
<td>4</td>
<td>Roche</td>
<td>$51.45B</td>
<td>$53.50B</td>
<td>+4.0%</td>
<td>Q1-Q3: Accelerating growth (2%, 5%, 9%); YTD: 6% CER growth; Mid-single-digit guidance</td>
</tr>
<tr>
<td>5</td>
<td>Johnson &amp; Johnson</td>
<td>$50.93B</td>
<td>$53.48B</td>
<td>+5.0%</td>
<td>Pharma segment steady at 5.5% growth</td>
</tr>
<tr>
<td>6</td>
<td>Sanofi</td>
<td>$46.59B</td>
<td>$52.97B</td>
<td>+13.7%</td>
<td>Accelerating growth (5.7%, 10.2%, 15.7%); Strong Q3: €13.44B; Raised EPS guidance</td>
</tr>
<tr>
<td>7</td>
<td>Novartis</td>
<td>$45.44B</td>
<td>$49.94B</td>
<td>+9.9%</td>
<td>Steady growth (7%, 9%, 10%); Low double-digit guidance; Strong operating income</td>
</tr>
<tr>
<td>8</td>
<td>Bristol-Myers Squibb</td>
<td>$45.01B</td>
<td>$47.44B</td>
<td>+5.4%</td>
<td>Consistent growth (5%, 9%, 8%); ~5% revenue growth guidance; Solid Q2 performance at 9%</td>
</tr>
<tr>
<td>9</td>
<td>Eli Lilly</td>
<td>$34.12B</td>
<td>$45.70B</td>
<td>+33.9%</td>
<td>Market leading Q2/Q3 (36%, 20%); Clear guidance: $45.4B-$46.0B; Strong momentum in key products</td>
</tr>
<tr>
<td>10</td>
<td>Novo Nordisk</td>
<td>$33.71B</td>
<td>$42.50B</td>
<td>+26.1%</td>
<td>Q3: 21% growth; Wegovy sales up 84%; Ozempic sales up 28%; Guidance: 23-27% growth</td>
</tr>
<tr>
<td>11</td>
<td>GSK</td>
<td>$37.73B</td>
<td>$40.23B</td>
<td>+6.6%</td>
<td>Strong H1 (10%, 13%); Q3 moderation to 2%; Guidance: 7-9% turnover growth</td>
</tr>
<tr>
<td>12</td>
<td>Amgen</td>
<td>$28.19B</td>
<td>$33.30B</td>
<td>+18.1%</td>
<td>Consistent 20%+ growth; Q1-Q3: 22%, 20%, 23%; Guidance: $32.8B-$33.8B</td>
</tr>
<tr>
<td>13</td>
<td>Takeda</td>
<td>$30.34B</td>
<td>$30.52B</td>
<td>+0.6%</td>
<td>Strong H1: 14.1%, 13.4% growth; Raised forecast to ¥4,480B; Better than initial flat guidance</td>
</tr>
<tr>
<td>14</td>
<td>Gilead</td>
<td>$27.12B</td>
<td>$27.95B</td>
<td>+3.1%</td>
<td>Q3: 7% growth; Key products growing (Biktarvy +13%); Guidance: $27.8B-$28.1B</td>
</tr>
<tr>
<td>15</td>
<td>Bayer AG</td>
<td>$17.78B</td>
<td>$17.23B</td>
<td>-3.0%</td>
<td>Q3 challenges: 3.6% revenue decline; EBITDA down 25.8%; Cautious 2025 outlook</td>
</tr>
<tr>
<td>16</td>
<td>Teva</td>
<td>$15.85B</td>
<td>$16.30B</td>
<td>+2.8%</td>
<td>Q3: 13% USD growth; Strong product performance; Guidance: $16.1B-$16.5B</td>
</tr>
<tr>
<td>17</td>
<td>Otsuka</td>
<td>$14.32B</td>
<td>$15.25B</td>
<td>+6.5%</td>
<td>Q3: 17% YoY growth; ¥1,730.1B forecast; Positive profit outlook</td>
</tr>
<tr>
<td>18</td>
<td>Viatris</td>
<td>$15.43B</td>
<td>$15.05B</td>
<td>-2.5%</td>
<td>Q3: 3% growth (divestiture-adjusted); Guidance: $14.6B-$15.1B; EBITDA: $5.0B-$5.3B target</td>
</tr>
<tr>
<td>19</td>
<td>CSL</td>
<td>$13.31B</td>
<td>$14.80B</td>
<td>+11.2%</td>
<td>CSL Behring: 14% growth; Seqirus: 4% growth; Strong NPATA growth</td>
</tr>
<tr>
<td>20</td>
<td>Regeneron</td>
<td>$13.12B</td>
<td>$13.85B</td>
<td>+5.6%</td>
<td>Q3: 11% growth; Dupixent sales +23%; Product sales guidance: $27.8B-$28.1B</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>排名</strong></th>
<th><strong>公司</strong></th>
<th><strong>2023 年收入</strong></th>
<th><strong>2024 年預測</strong></th>
<th><strong>預計增長</strong></th>
<th><strong>關鍵財務亮點</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>默克</td>
<td>$60.12B</td>
<td>$63.85B</td>
<td>+6.2%</td>
<td>Q1-Q3: 9%, 7%, 4% 增長軌跡；剔除外匯影響的強勁勢頭（Q1: 12%, Q3: 7%）；指導：$63.6B-$64.1B</td>
</tr>
<tr>
<td>2</td>
<td>輝瑞</td>
<td>$58.50B</td>
<td>$62.50B</td>
<td>+6.8%</td>
<td>Q3 顯示恢復：31% 增長；COVID 影響已納入指導；最近的指導上調：$61.0B-$64.0B</td>
</tr>
<tr>
<td>3</td>
<td>阿斯利康</td>
<td>$45.81B</td>
<td>$54.00B</td>
<td>+17.9%</td>
<td>一致的高個位數增長（Q1-Q3: 19%, 17%, 21%）；年初至今：$39.18B (+19%); 各季度強勁勢頭。指導在 “高個位數” 範圍內。</td>
</tr>
<tr>
<td>4</td>
<td>羅氏</td>
<td>$51.45B</td>
<td>$53.50B</td>
<td>+4.0%</td>
<td>Q1-Q3: 加速增長（2%, 5%, 9%）；年初至今：6% CER 增長；中個位數指導</td>
</tr>
<tr>
<td>5</td>
<td>強生</td>
<td>$50.93B</td>
<td>$53.48B</td>
<td>+5.0%</td>
<td>製藥部門穩定在 5.5% 增長</td>
</tr>
<tr>
<td>6</td>
<td>賽諾菲</td>
<td>$46.59B</td>
<td>$52.97B</td>
<td>+13.7%</td>
<td>加速增長（5.7%, 10.2%, 15.7%）；強勁的 Q3：€13.44B；上調每股收益指導</td>
</tr>
<tr>
<td>7</td>
<td>諾華</td>
<td>$45.44B</td>
<td>$49.94B</td>
<td>+9.9%</td>
<td>穩定增長（7%, 9%, 10%）；低雙位數指導；強勁的營業收入</td>
</tr>
<tr>
<td>8</td>
<td>百時美施貴寶</td>
<td>$45.01B</td>
<td>$47.44B</td>
<td>+5.4%</td>
<td>一致增長（5%, 9%, 8%）；~5% 收入增長指導；Q2 表現穩健，增長 9%</td>
</tr>
<tr>
<td>9</td>
<td>禮來</td>
<td>$34.12B</td>
<td>$45.70B</td>
<td>+33.9%</td>
<td>市場領先的 Q2/Q3（36%, 20%）；明確的指導：$45.4B-$46.0B；關鍵產品強勁勢頭</td>
</tr>
<tr>
<td>10</td>
<td>諾和諾德</td>
<td>$33.71B</td>
<td>$42.50B</td>
<td>+26.1%</td>
<td>Q3: 21% 增長；Wegovy 銷售增長 84%；Ozempic 銷售增長 28%；指導：23-27% 增長</td>
</tr>
<tr>
<td>11</td>
<td>GSK</td>
<td>$37.73B</td>
<td>$40.23B</td>
<td>+6.6%</td>
<td>強勁的上半年（10%, 13%）；Q3 放緩至 2%；指導：7-9% 營業額增長</td>
</tr>
<tr>
<td>12</td>
<td>安進</td>
<td>$28.19B</td>
<td>$33.30B</td>
<td>+18.1%</td>
<td>一致的 20%+ 增長；Q1-Q3: 22%, 20%, 23%；指導：$32.8B-$33.8B</td>
</tr>
<tr>
<td>13</td>
<td>武田</td>
<td>$30.34B</td>
<td>$30.52B</td>
<td>+0.6%</td>
<td>強勁的上半年：14.1%, 13.4% 增長；上調預測至¥4,480B；優於最初的平穩指導</td>
</tr>
<tr>
<td>14</td>
<td>吉利德</td>
<td>$27.12B</td>
<td>$27.95B</td>
<td>+3.1%</td>
<td>Q3: 7% 增長；關鍵產品增長（Biktarvy +13%）；指導：$27.8B-$28.1B</td>
</tr>
<tr>
<td>15</td>
<td>拜耳</td>
<td>$17.78B</td>
<td>$17.23B</td>
<td>-3.0%</td>
<td>Q3 挑戰：3.6% 收入下降；EBITDA 下降 25.8%；謹慎的 2025 年展望</td>
</tr>
<tr>
<td>16</td>
<td>Teva</td>
<td>$15.85B</td>
<td>$16.30B</td>
<td>+2.8%</td>
<td>Q3: 13% 美元增長；強勁的產品表現；指導：$16.1B-$16.5B</td>
</tr>
<tr>
<td>17</td>
<td>大冢</td>
<td>$14.32B</td>
<td>$15.25B</td>
<td>+6.5%</td>
<td>Q3: 同比增長 17%；¥1,730.1B 預測；積極的利潤展望</td>
</tr>
<tr>
<td>18</td>
<td>Viatris</td>
<td>$15.43B</td>
<td>$15.05B</td>
<td>-2.5%</td>
<td>Q3: 3% 增長（剔除剝離影響）；指導：$14.6B-$15.1B；EBITDA：$5.0B-$5.3B 目標</td>
</tr>
<tr>
<td>19</td>
<td>CSL</td>
<td>$13.31B</td>
<td>$14.80B</td>
<td>+11.2%</td>
<td>CSL Behring: 14% 增長；Seqirus: 4% 增長；強勁的 NPATA 增長</td>
</tr>
<tr>
<td>20</td>
<td>Regeneron</td>
<td>$13.12B</td>
<td>$13.85B</td>
<td>+5.6%</td>
<td>Q3: 11% 增長；Dupixent 銷售增長 23%；產品銷售指導：$27.8B-$28.1B</td>
</tr>
</tbody>
</table>
</div><h3>Methodology</h3>
<div class="lb-trans"><h3>方法論</h3>
</div><p>The revenue projections for 2024 were initially based on financial figures derived from the trailing four quarters of reported revenue and from the companies’ guidance. Data from company reports and finbox.com. For companies offering direct guidance, projections were aligned with the midpoint of the guidance ranges. For companies providing growth-rate guidance rather than specific revenue targets, projections were calculated using the implied growth ranges.</p>
<div class="lb-trans"><p>2024 年的收入預測最初基於過去四個季度報告的財務數據和公司的指導。數據來自公司報告和 finbox.com。對於提供直接指導的公司，預測與指導範圍的中點對齊。對於提供增長率指導而非具體收入目標的公司，預測是根據隱含的增長範圍計算的。</p>
</div><p>Diversified companies required segment-specific adjustments to accurately estimate pharmaceutical revenue. These adjustments included segment contributions of 63.67% for Johnson &amp; Johnson, 71.6% for Roche, 33.8% for Bayer, 37.6% for Merck KGaA, and 13.0% for Abbott.</p>
<div class="lb-trans"><p>多元化公司需要針對特定細分市場進行調整，以準確估計製藥收入。這些調整包括強生 63.67%、羅氏 71.6%、拜耳 33.8%、默克 KGaA37.6% 和雅培 13.0% 的細分貢獻。</p>
</div><hr/>
<div class="lb-trans"><hr/>
</div><hr/>
<div class="lb-trans"><hr/>
</div>

Projecting the top 20 Big Pharma firms of FY2024

- 製藥行業面臨激烈競爭，2024 年收入預測顯示領導者動態變化。  
- 阿斯利康、禮來和諾和諾德的增長率分別為 17.9%、33.9% 和 26.1%。  
- 阿斯利康預計 2024 年總收入和核心每股收益將實現高單位數增長。  

預測 2024 財年排名前 20 的大型製藥企業